Cargando…
A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer
To assess clinical utility of the 21-gene assay (Oncotype DX(®) Recurrence Score(®)), we determined whether women with HER2(−)/ER+ pN1mi breast cancer with low (<18) Recurrence Scores results are given adjuvant chemotherapy in a lower proportion than those with high scores (≥31). This was a multi...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381203/ https://www.ncbi.nlm.nih.gov/pubmed/25789420 http://dx.doi.org/10.3390/ph8010107 |
_version_ | 1782364411513536512 |
---|---|
author | Frazier, Thomas G. Fox, Kevin R. Smith, J. Stanley Laronga, Christine McSwain, Anita Paul, Devchand Schultz, Michael Stilwill, Joseph Teal, Christine Weisberg, Tracey Vacchino, Judith F. Sing, Amy P. Cherepanov, Dasha Hsiao, Wendy Chang, Eunice Broder, Michael S. |
author_facet | Frazier, Thomas G. Fox, Kevin R. Smith, J. Stanley Laronga, Christine McSwain, Anita Paul, Devchand Schultz, Michael Stilwill, Joseph Teal, Christine Weisberg, Tracey Vacchino, Judith F. Sing, Amy P. Cherepanov, Dasha Hsiao, Wendy Chang, Eunice Broder, Michael S. |
author_sort | Frazier, Thomas G. |
collection | PubMed |
description | To assess clinical utility of the 21-gene assay (Oncotype DX(®) Recurrence Score(®)), we determined whether women with HER2(−)/ER+ pN1mi breast cancer with low (<18) Recurrence Scores results are given adjuvant chemotherapy in a lower proportion than those with high scores (≥31). This was a multicenter chart review of ≥18 year old women with pN1mi breast cancer, HER2(−)/ER+ tumors, ductal/lobular/mixed histology, with the assay ordered on or after 1 January 2007. One hundred and eighty one patients had a mean age of 60.7 years; 82.9% had ECOG performance status 0; 33.7% had hypertension, 22.7% had osteoporosis, 18.8% had osteoarthritis, and 8.8% had type-2 diabetes. Mean Recurrence Score was 17.8 (range: 0–50). 48.6% had a mastectomy; 55.8% had a lumpectomy. 19.8% of low-risk group patients were recommended chemotherapy vs. 57.9% in the intermediate-risk group and 100% in the high-risk group (p < 0.001). A total of 80.2% of the low-risk group were recommended endocrine therapy alone, while 77.8% of the high-risk group were recommended both endocrine and chemotherapy (p < 0.001). The Oncotype DX Recurrence Score result provides actionable information that can be incorporated into treatment planning for women with HER2(−)/ER+ pN1mi breast cancer. The Recurrence Score result has clinical utility in treatment planning for HER2(−)/ER+ pN1mi breast cancer patients. |
format | Online Article Text |
id | pubmed-4381203 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-43812032015-04-30 A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer Frazier, Thomas G. Fox, Kevin R. Smith, J. Stanley Laronga, Christine McSwain, Anita Paul, Devchand Schultz, Michael Stilwill, Joseph Teal, Christine Weisberg, Tracey Vacchino, Judith F. Sing, Amy P. Cherepanov, Dasha Hsiao, Wendy Chang, Eunice Broder, Michael S. Pharmaceuticals (Basel) Article To assess clinical utility of the 21-gene assay (Oncotype DX(®) Recurrence Score(®)), we determined whether women with HER2(−)/ER+ pN1mi breast cancer with low (<18) Recurrence Scores results are given adjuvant chemotherapy in a lower proportion than those with high scores (≥31). This was a multicenter chart review of ≥18 year old women with pN1mi breast cancer, HER2(−)/ER+ tumors, ductal/lobular/mixed histology, with the assay ordered on or after 1 January 2007. One hundred and eighty one patients had a mean age of 60.7 years; 82.9% had ECOG performance status 0; 33.7% had hypertension, 22.7% had osteoporosis, 18.8% had osteoarthritis, and 8.8% had type-2 diabetes. Mean Recurrence Score was 17.8 (range: 0–50). 48.6% had a mastectomy; 55.8% had a lumpectomy. 19.8% of low-risk group patients were recommended chemotherapy vs. 57.9% in the intermediate-risk group and 100% in the high-risk group (p < 0.001). A total of 80.2% of the low-risk group were recommended endocrine therapy alone, while 77.8% of the high-risk group were recommended both endocrine and chemotherapy (p < 0.001). The Oncotype DX Recurrence Score result provides actionable information that can be incorporated into treatment planning for women with HER2(−)/ER+ pN1mi breast cancer. The Recurrence Score result has clinical utility in treatment planning for HER2(−)/ER+ pN1mi breast cancer patients. MDPI 2015-03-17 /pmc/articles/PMC4381203/ /pubmed/25789420 http://dx.doi.org/10.3390/ph8010107 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Frazier, Thomas G. Fox, Kevin R. Smith, J. Stanley Laronga, Christine McSwain, Anita Paul, Devchand Schultz, Michael Stilwill, Joseph Teal, Christine Weisberg, Tracey Vacchino, Judith F. Sing, Amy P. Cherepanov, Dasha Hsiao, Wendy Chang, Eunice Broder, Michael S. A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer |
title | A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer |
title_full | A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer |
title_fullStr | A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer |
title_full_unstemmed | A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer |
title_short | A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer |
title_sort | retrospective study of the impact of 21-gene recurrence score assay on treatment choice in node positive micrometastatic breast cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4381203/ https://www.ncbi.nlm.nih.gov/pubmed/25789420 http://dx.doi.org/10.3390/ph8010107 |
work_keys_str_mv | AT frazierthomasg aretrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT foxkevinr aretrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT smithjstanley aretrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT larongachristine aretrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT mcswainanita aretrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT pauldevchand aretrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT schultzmichael aretrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT stilwilljoseph aretrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT tealchristine aretrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT weisbergtracey aretrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT vacchinojudithf aretrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT singamyp aretrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT cherepanovdasha aretrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT hsiaowendy aretrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT changeunice aretrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT brodermichaels aretrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT frazierthomasg retrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT foxkevinr retrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT smithjstanley retrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT larongachristine retrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT mcswainanita retrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT pauldevchand retrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT schultzmichael retrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT stilwilljoseph retrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT tealchristine retrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT weisbergtracey retrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT vacchinojudithf retrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT singamyp retrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT cherepanovdasha retrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT hsiaowendy retrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT changeunice retrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer AT brodermichaels retrospectivestudyoftheimpactof21generecurrencescoreassayontreatmentchoiceinnodepositivemicrometastaticbreastcancer |